This work introduces the procedure of using nonimmunoassay distance-based paper analytical devices (dPADs) to accurately measure any traces of the cardiac troponin I (TnI) in whole blood samples without the use of any external blood separation. This enables a rapid clinical diagnosis and the subsequent follow-up in regard to identifying acute myocardial infarction. These dPADs are designed and constructed to accommodate three parts: (1) a blood separation zone that is immobilized with a hemostatic agent, this no longer requires a blood separation membrane for the isolation of the plasma from the blood element, (2) a pretreatment zone, and (3) a detection zone coated with thymol blue. The quantitative TnI level in the whole blood was determined by measuring the blue color length found in the detection zone, which is proportional to the concentration, owing to the dry protein binding principle. Correspondingly, a mere single drop of human whole blood performs adequately within our proposed method. This reduces both the size of the collection process and the sample volumes needed in the respective medical fields. As we cover all of the optimization studies, our dPADs provide an evaluation of the linearity range from 0.025 to 2.5 ng/mL (R 2 = 0.9989) of TnI, with a detection limit as low as 0.025 ng/mL by use of an observation just using the naked eye. To validate the clinical utilities of our proposed method, our dPADs were then applied for the detection of TnI in humans using the whole blood sample of 15 volunteers. A great amount of accuracy was required in this assay because there was no significant difference between both methods, with the confidence level being as high as 95%. This technique also showed that the recoveries ranged from 99.40 to 104.27%, with the highest relative standard deviation being at 3.77%. Thus, our proposed dPADs offer more benefits for a rapid TnI determination.

In this work, we developed the first ultrasound technique enhanced smartphone application for highly sensitive determination of hydrogen peroxide (H2O2).

We report the development of a distance-based paper analytical device combined with a hydrophilic bridge valve (B-dPAD) as a quantitative immunoassay method to monitor human interleukin-6 (IL-6) in human samples. Our device design features (i) a circular sample inlet zone, (ii) a circular capture zone with immobilized anti-IL-6 (anti-Ab 1 ), and (iii) a detection zone channel coated with methylene blue (MB). Two hydrophilic valves are positioned between these three zones. IL-6 levels were determined quantitatively by measuring the extent of degradation of MB to a colorless product along the length of the detection zone channel. Following method optimization, we obtained a linear range from 0.05 to 25.0 pg/mL (R 2 = 0.9995) and a detection limit (LOD) of 0.05 pg/mL by the naked-eye readout. This is directly within the clinically relevant range. The system does not require any external instrumentation, and the bridge valves can be easily connected and disconnected by a minimally trained operator. The total analysis time is 35 min, significantly reduced from a typical ELISA assay, which takes around 1 h since the B-dPAD workflow circumvents washing steps. The device was tested for IL-6 quantification in human saliva and urine samples of volunteers, with no significant difference found between our method and the standard clinical laboratory method at 95% confidence levels. Recoveries ranged from 98 to 105% with the highest standard deviation at 3.9%. Our B-dPAD immunodevice is therefore a promising approach for rapid IL-6 monitoring in the context of point-of-care diagnostics and analysis in resource-limited settings.

The simple reflective absorbance spectrophotometric smartphone device for point-ofmonitoring amlodipine is presented here for the first time. The immediate analysis of amlodipine in the human urine of the patients who suffered severe side effects of this drug is very important for diagnosis, treatment, and reduction of the death rate. This measurement technique is based on the charge-transfer complex between amlodipine and picric acid, which forms a yellow product. This product can absorb light intensity from an LED strip and measure through the Blue channel from RGB mode with a smartphone application. The linear relationship for amlodipine monitoring was found in a wide range from 100.0 µg L-1 to 140.0 mg L-1 (R 2 = 0.999), and the limit of detection was found to be 25.0 µg L-1. Our proposed method can be applied to the different smartphone brands with consistent sensitivity of amlodipine detection. Additionally, the determination of amlodipine in pharmaceutical formulation and human urine samples was demonstrated by our proposed method. The recoveries were indicated in the range 98.60-100.00%, which is at the acceptable level for pharmacy. This method offers interweave of basic technology and chemical analysis with environmentally friendly due to reducing the complex instrument and the amount of organic waste compared to chromatographic technique and efficient use for the detection of amlodipine. Hence, this method can be applied for promptly medical diagnoses and laboratories with limited budget resources.